The Journal of Clinical Investigation (Jun 2023)

KIR-HLA interactions extend human CD8+ T cell lifespan in vivo

  • Yan Zhang,
  • Ada W.C. Yan,
  • Lies Boelen,
  • Linda Hadcocks,
  • Arafa Salam,
  • Daniel Padrosa Gispert,
  • Loiza Spanos,
  • Laura Mora Bitria,
  • Neda Nemat-Gorgani,
  • James A. Traherne,
  • Chrissy Roberts,
  • Danai Koftori,
  • Graham P. Taylor,
  • Daniel Forton,
  • Paul J. Norman,
  • Steven G.E. Marsh,
  • Robert Busch,
  • Derek C. Macallan,
  • Becca Asquith

Journal volume & issue
Vol. 133, no. 12

Abstract

Read online

BACKGROUND There is increasing evidence, in transgenic mice and in vitro, that inhibitory killer cell immunoglobulin-like receptors (iKIRs) can modulate T cell responses. Furthermore, we have previously shown that iKIRs are an important determinant of T cell–mediated control of chronic viral infection and that these results are consistent with an increase in the CD8+ T cell lifespan due to iKIR-ligand interactions. Here, we tested this prediction and investigated whether iKIRs affect T cell lifespan in humans in vivo.METHODS We used stable isotope labeling with deuterated water to quantify memory CD8+ T cell survival in healthy individuals and patients with chronic viral infections.RESULTS We showed that an individual’s iKIR-ligand genotype was a significant determinant of CD8+ T cell lifespan: in individuals with 2 iKIR-ligand gene pairs, memory CD8+ T cells survived, on average, for 125 days; in individuals with 4 iKIR-ligand gene pairs, the memory CD8+ T cell lifespan doubled to 250 days. Additionally, we showed that this survival advantage was independent of iKIR expression by the T cell of interest and, further, that the iKIR-ligand genotype altered the CD8+ and CD4+ T cell immune aging phenotype.CONCLUSIONS Together, these data reveal an unexpectedly large effect of iKIR genotype on T cell survival.FUNDING Wellcome Trust; Medical Research Council; EU Horizon 2020; EU FP7; Leukemia and Lymphoma Research; National Institute of Health Research (NIHR) Imperial Biomedical Research Centre; Imperial College Research Fellowship; National Institutes of Health; Jefferiss Trust.

Keywords